RiaSTAP FDA Approval History
FDA Approved: Yes (First approved January 16, 2009)
Brand name: RiaSTAP
Generic name: Fibrinogen Concentrate (Human)
Company: CSL Behring
Treatment for: Congenital Fibrinogen Deficiency
RiaSTAP (Fibrinogen Concentrate (Human)) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia.
Development Timeline for RiaSTAP
|Jan 20, 2009||Approval CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.